title: Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma.
abstract: OBJECTIVE
  To investigate the efficacy and safety of lobaplatin-transcatheter arterial chemoembolization (TACE) combined with radioactive 125I seed implantation in treatment of primary hepatocellular carcinoma (HCC).
  
  
  METHODS
  75 patients with primary HCC were enrolled in the study, among them 43 receiving lobaplatin- TACE (TACE group) and 32 lobaplatin-TACE combined with 125I seed implantation (TACE+125I group). After treatment, the local remission rates and postoperative complications of two groups were compared using the Pearson Chi-square test. Overall survival in the two groups was calculated using Kaplan-Meier survival curves and the differences were tested using Log-rank test.
  
  
  RESULTS
  There were 7 cases of complete response (CR), 13 of partial response (PR), 6 of stable disease (SD) and 17 of progressive disease (PD) in the TACE group, with 13 cases of CR, 9 of PR, 5 of SD and 5 of PD in the TACE+125I group. The disease control rates of TACE and TACE+125I group were 60.5% (26/43) and 84.4% (27/32), respectively, with a significant difference between them (P < 0.05). The survival rates at 6, 12 and 18 months in the TACE group were 100.0%, 81.8% and 50.0%, respectively, and those in TACE+125I group were 100.0%, 93.8% and 65.6%. The mean survival times in the TACE and TACE+125I groups were 19.5 and 22.9 months, respectively. There was a significant difference in the overall survival rate between two groups (P < 0.05). No serious complications were encountered in either group.
  
  
  CONCLUSIONS
  Lobaplatin-TACE combined with 125I seed implantation is favorable and safe for treatment of primary HCC.
authors.affiliation: Department of Medical Imaging and Minimally Invasive Interventional Center; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China E-mail : fujunzhangcn@126.com.
authors.forename: Sheng
authors.initials: S
authors.lastname: Peng
authors.forename: Qiu-Xia
authors.initials: QX
authors.lastname: Yang
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Ming-Jian
authors.initials: MJ
authors.lastname: Lu
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Zhen-Yin
authors.initials: ZY
authors.lastname: Liu
authors.forename: Rong
authors.initials: R
authors.lastname: Zhang
authors.forename: Fu-Jun
authors.initials: FJ
authors.lastname: Zhang
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods; D003131:Combined Modality Therapy / Q000379:methods; D003503:Cyclobutanes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000494:pharmacology*; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003503:Cyclobutanes; D007457:Iodine Radioisotopes; D009944:Organoplatinum Compounds; C066228:lobaplatin